Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance
Status:
Active, not recruiting
Trial end date:
2022-11-11
Target enrollment:
Participant gender:
Summary
This is a hypothesis driven, open label, single-arm, multiple centers, Phase II trial. The
trial has been designed to prove or disprove whether a rechallenge with panitumumab can
achieve an objective response rate (ORR= CR+PR) of 30% or more in a population of RAS wild
type mCRC patients selected on the basis of RAS extended clonal evolution in their plasma.